Topoisomerase I activity in squamous cell carcinoma of the head and neck.

Abstract

In recent preclinical and clinical trials, topoisomerase I inhibitors have shown great promise as antitumor agents. These agents are most effective against tumors with high topoisomerase I activity. Therefore, determining topoisomerase I activity in advance may predict response to topoisomerase I inhibitors. Squamous cell carcinoma of the head and neck and normal tissue samples were obtained from 12 patients. Cellular extracts were prepared, and topoisomerase I activity assays were performed. The results suggest that topoisomerase I activity in squamous cell carcinoma of the head and neck is increased approximately sixtyfold compared to normal tissue. Increased activity often correlates with clinical responsiveness; these results predict that topoisomerase I inhibitors should be effective and selective against squamous cell carcinoma of the head and neck.

• Authors: J S Masin, S J Berger, S Setrakian, D W Stepnick, N A Berger
• Journal: The Laryngoscope (Laryngoscope) Vol. 105 Issue 11 Pg. 1191-6 (Nov 1995) ISSN: 0023-852X [Print] United States
• PMID: 7475874 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Enzyme Inhibitors
• Topoisomerase I Inhibitors
• DNA Topoisomerases, Type I

Topics

• Aged
• Aged, 80 and over
• Biopsy
• Carcinoma, Squamous Cell (drug therapy, enzymology, pathology)
• DNA Topoisomerases, Type I (metabolism)
• Enzyme Inhibitors (therapeutic use)
• Female
• Head and Neck Neoplasms (drug therapy, enzymology, pathology)
• Humans
• Linear Models
• Male
• Middle Aged
• Topoisomerase I Inhibitors